Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116896 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
A Phase 1 study, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00116896 is a Phase 1 study that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT00116896, a Phase 1 study, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.
Interventions
- DRUG Cisplatin
- DRUG OSI-7904L
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116896
The ClinicalTrials.gov registry entry for NCT00116896 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT00116896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116896 about?
NCT00116896 is a clinical study titled "Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors". This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.
What is the current status of trial NCT00116896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2003-06. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00116896?
The interventions under investigation include: Cisplatin (DRUG), OSI-7904L (DRUG).
Who is sponsoring clinical trial NCT00116896?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.